PubRank

Cancer Vaccine Study for Stage III, Unresectable, Non-small Cell Lung Cancer (NSCLC) in the Asian Population (INSPIRE)

Clinical Trial ID NCT01015443

PubWeight™ 23.66‹?›

🔗 Visit the ClinicalTrials.gov page for NCT01015443

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Breathing new life into immunotherapy: review of melanoma, lung and kidney cancer. Nat Rev Clin Oncol 2013 2.64
2 Trial watch: Chemotherapy with immunogenic cell death inducers. Oncoimmunology 2012 1.33
3 Trial watch: Peptide vaccines in cancer therapy. Oncoimmunology 2012 1.17
4 Molecular pathways and therapeutic targets in lung cancer. Oncotarget 2014 1.16
5 Multiple therapeutic peptide vaccines consisting of combined novel cancer testis antigens and anti-angiogenic peptides for patients with non-small cell lung cancer. J Transl Med 2013 1.06
6 Therapeutic cancer vaccines: past, present, and future. Adv Cancer Res 2013 0.99
7 Advances in immunotherapy for treatment of lung cancer. Cancer Biol Med 2015 0.95
8 New modalities of cancer treatment for NSCLC: focus on immunotherapy. Cancer Manag Res 2014 0.94
9 Immunotherapy for Lung Cancer: Has it Finally Arrived? Front Oncol 2014 0.94
10 INSPIRE: A phase III study of the BLP25 liposome vaccine (L-BLP25) in Asian patients with unresectable stage III non-small cell lung cancer. BMC Cancer 2011 0.92
11 Novel approaches of chemoradiotherapy in unresectable stage IIIA and stage IIIB non-small cell lung cancer. Oncologist 2012 0.91
12 Immunotherapy for lung cancer: advances and prospects. Am J Clin Exp Immunol 2016 0.89
13 Liposome-Based Adjuvants for Subunit Vaccines: Formulation Strategies for Subunit Antigens and Immunostimulators. Pharmaceutics 2016 0.83
14 Cross-sectional and longitudinal analysis of cancer vaccination trials registered on the US Clinical Trials Database demonstrates paucity of immunological trial endpoints and decline in registration since 2008. Drug Des Devel Ther 2014 0.82
15 Immunotherapy in lung cancer. Transl Lung Cancer Res 2014 0.82
16 Locally advanced lung cancer: an optimal setting for vaccines and other immunotherapies. Cancer J 2013 0.82
17 Tecemotide: an antigen-specific cancer immunotherapy. Hum Vaccin Immunother 2014 0.81
18 What lies within: novel strategies in immunotherapy for non-small cell lung cancer. Oncologist 2013 0.81
19 Cellular and molecular immunology of lung cancer: therapeutic implications. Expert Rev Clin Immunol 2014 0.79
20 Evaluating the efficacy of therapeutic HIV vaccines through analytical treatment interruptions. J Int AIDS Soc 2015 0.78
21 Next-generation cancer vaccine approaches: integrating lessons learned from current successes with promising biotechnologic advances. J Natl Compr Canc Netw 2013 0.77
22 Immunotherapy for non-small cell lung cancer: current concepts and clinical trials. Eur J Cardiothorac Surg 2015 0.77
23 Evaluation of tumour vaccine immunotherapy for the treatment of advanced non-small cell lung cancer: a systematic meta-analysis. BMJ Open 2015 0.76
24 Therapeutic cancer vaccines and combination immunotherapies involving vaccination. Immunotargets Ther 2014 0.75
25 Unresectable stage III non-small cell lung cancer: is Tecemotide a new START for our patients? J Thorac Dis 2014 0.75
Next 100